Member Login

Dr. Samantha Gouw

MD, PhD

Biography

Samantha C. Gouw, MD, PhD is trained as a pediatric hematologist and clinical epidemiologist. She received her PhD doctorate on the etiology of inhibitor development in children with severe hemophilia A at Utrecht University in 2011. In collaboration with a team of international colleagues, she published several papers in Blood and New England Journal of Medicine on genetic and non-genetic risk factors of inhibitor development. She currently works as a clinician-researcher at the Department of Pediatric Hematology at the Amsterdam University Medical Center. She is the coordinating researcher of a nationwide study and biobank in hemophilia patients at the Department of Clinical Epidemiology at Leiden University Medical center, The Netherlands and is a work package leader in the National Symphony Consortium. Her current research focuses on inhibitor development and immune tolerance induction and the quality of hemophilia care, especially e-health and value based health care.

Key Publications

  • S.C. Gouw, J.G. van der Bom, R. Ljung, C. Escuriola, A.R. Cid, S.Claeyssens-Donadel, C. van Geet, G. Kenet, A. Mäkipernaa, A. Claudio Molinari, W. Muntean, R. Kobelt, G. Rivard, E. Santagostino, A. Thomas, H. M. van den Berg. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013;368:231-9.

  • S.C. Gouw, H.M. van den Berg, K. Fischer, G. Auerswald, M. Carcao, E. Chalmers, H. Chambost, K. Kurnik, R. Liesner, P. Petrini, H. Platokouki, C. Altisent, J. Oldenburg, B. Nolan, R. Pérez Garrido, M.E. Mancuso, A. Rafowicz, M. Williams, N. Clausen, R.A. Middelburg, R. Ljung, J.G. van der Bom, for the PedNet and RODIN Study Group. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013;121:4046-55.

  • S.C. Gouw, H.M. van den Berg, J. Astermark, J. Oldenburg, M. Margaglione, A. Thompson, J. Boekhorst, C.H.Miller, Ph.G. de Groot, J.G. van der Bom. F8 gene mutation type and inhibitor development in patients with severe Hemophilia A: systematic review and meta-analysis. Blood 2012;119:2922-34.

  • 4. A. Abdi, M.R. Bordbar, S. Hassan, F.R. Rosendaal, J.G. van der Bom, J. Voorberg, K. Fijnvandraat, S.C. Gouw. Prevalence and incidence of non-neutralizing antibodies in congenital hemophilia A- a systematic review and meta-analysis. Front Immunol. 2020;11:563.

  • 5. S. Hassan, R.C. Monahan, E.P. Mauser-Bunschoten, L.F.D. van Vulpen, J. Eikenboom, E.A.M. Beckers, L. Hooimeijer, P.F. Ypma, L. Nieuwenhuizen, M. Coppens, S.E.M. Schols, F.W.G. Leebeek, C. Smit, M.H. Driessens, S. le Cessie, E.C. van Balen, F.R. Rosendaal, J.G. van der Bom, S.C. Gouw. Mortality, life expectancy and causes of death of persons with hemophilia in the Netherlands 2001-2018. J Thromb Haemost. 2020;19:645-53.

Key Institutions

  • Amsterdam University Medical Center
    Pediatric Hematology
    Amsterdam, Netherlands

Current Positions/Chairs

  • Clinician – Researcher

Research Activities

  • FREE study, effects of emicizumab prophylaxis in severe hemophilia A. Initiator and coordinating researcher, supervision of L. van Stam, PhD student

  • GRIP study, role of Fc gamma receptors in immune tolerance to FVIII. Initiator and supervision of I. Oomen, PhD student

  • Symphony E-Health & Value-based health care coagulation disorders. Workpackage leader E-Health, supervision M.R. Brands, E.S. van Hoorn, PhD students.

  • DYNAMO, The Dynamic interplay between bleeding phenotype and baseline factor level in moderate and mild hemophilia A and B’. Supervision of A.F. Zwagemaker, F. Kloosterman, PhD students.